



News Release

Suven Life Sciences at Society for Neuroscience (SFN-2015) Chicago. Presenting data on several of their NCE's.

HYDERABAD, INDIA (Oct 19th, 2015) – Suven Life Sciences is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) at SFN 2015 being held at Chicago, USA during 17-21, 2015. Neuroscience is the annual meeting of the Society for Neuroscience (SFN) and more than 25 thousand Neuro-Scientists from all over the world covering the major Pharma, Biotech and Clinical Research institutes will be participating at this conference

Key pharmacology, ADME, Safety and Phase-1 clinical data on SUVN-502 (5-HT6 receptor antagonist), SUVN-G3031 (Histamine-3 receptor antagonist), SUVN-D4010 (5-HT4 receptor partial agonist), CB2 agonist and Muscarinic (M1) acetylcholine receptor positive allosteric modulators (PAM) to treat the unmet medical needs of patients living with cognitive dysfunction associated with Alzheimer's, Schizophrenia, ADHD; Depression & Mood Disorders and Neuropathic Pain are being presented by Suven scientists at SFN-2015. These data presentations highlight Suven's continued commitment to explore new treatment options addressing unmet medical need through novel mechanisms and targets and address a market size of more than \$35 billion.

During SFN-2015 Suven lined up several face to face meetings with major Pharma and Biotech companies to explore integrated collaborative research programs (CRP), Discovery and Development Support Services (DDDSS) and continued discussions with global pharma majors for potential partnering and out licensing of the clinical candidate SUVN-502.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. Suven has 3 clinical stage compounds, a Phase 2 initiated candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 initiated candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia. In addition to that the Company has ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;